Cerebrovascular Complications of Diabetes: Alpha Glucosidase Inhibitor as Potential Therapy

Hormone and Metabolic Research

Volumn 48, Issue 2, 2015, Pages 83-91

  Patel, S S ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

cerebrovascular accident; diabetes; hyperglycemia; vascular damage; glucosidase inhibitors

Indexed keywords

ACARBOSE; ADVANCED GLYCATION END PRODUCT; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; EXENDIN 4; GELATINASE B; GLIBENCLAMIDE; GLUCOSE; HEXOSAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 6; METFORMIN; MIGLITOL; PIOGLITAZONE; POLYOL SORBITOL; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SORBITOL; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VOGLIBOSE; GLYCOSIDASE INHIBITOR;

BLOOD VESSEL INJURY; BRAIN BLOOD VESSEL; CEREBROVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; FLATULENCE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; RISK FACTOR; RISK REDUCTION; STOMACH PAIN; VASCULAR ENDOTHELIUM; DIABETES COMPLICATIONS; METABOLISM; PATHOLOGY; STROKE;

DIABETES COMPLICATIONS; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; STROKE;

EID: 84947815650     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0035-1565181     Document Type: Review

References (99)

1. Zhang M., Chen P., Chen S., Sun Q., Zeng Q. C., Chen J. Y., Liu Y. X., Cao X. H., Ren M., Wang J. K. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci: 2014; 18 1567 1572
2. Woodruff T. M., Thundyil J., Tang S. C., Sobey C. G., Taylor S. M., Arumugam T. V. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener: 2011; 6 11
3. Seshadri S., Beiser A., Kelly-Hayes M., Kase C. S., Au R., Kannel W. B., Wolf P. A. The lifetime risk of stroke: estimates from the Framingham Study. Stroke: 2006; 37 345 350
4. Shah B., Mathur P. Workshop Report on Stroke Surveillance in India. Division of Noncommunicable Diseases. Indian Council of Medical Research New Delhi: 2006
5. Giorda C. B., Avogaro A., Maggini M., Lombardo F., Mannucci E., Turco S., Alegiani S. S., Raschetti R., Velussi M., Ferrannini E. Group DAIS Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke: 2007; 38 1154 1160
6. Kissela B. M., Khoury J., Kleindorfer D., Woo D., Schneider A., Alwell K., Miller R., Ewing I., Moomaw C. J., Szaflarski J. P., Gebel J., Shukla R., Broderick J. P. Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care: 2005; 28 355 359
7. Marso S. P., Kennedy K. F., House J. A., McGuire D. K. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Vasc Dis Res: 2010; 7 119 130
8. Sturgeon J. D., Folsom A. R., Longstreth W. T. Jr, Shahar E., Rosamond W. D., Cushman M. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke: 2007; 38 2718 2725
9. Rosamond W. D., Folsom A. R., Chambless L. E., Wang C. H., McGovern P. G., Howard G., Copper L. S., Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke: 1999; 30 736 743
10. McEwen B. S., Reagan L. P. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol: 2004; 490 13 24
11. Haidari M., Zhang W., Willerson J. T., Dixon R. A. Disruption of endothelial adherens junctions by high glucose is mediated by protein kinase C-beta-dependent vascular endothelial cadherin tyrosine phosphorylation. Cardiovascul Diabetol: 2014; 13 112
12. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature: 2001; 414 813 820
13. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengeller Z., Szabo C., Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Investig: 2003; 112 1049 1057
14. Martini S. R., Kent T. A. Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab: 2007; 27 435 451
15. Vazzana N., Ranalli P., Cuccurullo C., Davi G. Diabetes mellitus and thrombosis. Thromb Res: 2012; 129 371 377
16. Fagot-Campagna A., Rolka D. B., Beckles G. L., Gregg E. W., Narayan K. M. Prevalence of lipid ablormalities, awareness, and treatment in US adults with diabetes (Abstract). Diabetes: 2000; 49 01 A78
17. Festa A., D'Agostino R. Jr, Mykkanen L., Tracy R. P., Hales C. N., Howard B. V., Haffner S. M. LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. The Insulin Resistance Atherosclerosis Study. Diabetes Care: 1999; 22 1688 1693
18. Chan A. C. Vitamin E and atherosclerosis. J Nutr: 1998; 128 1593 1596
19. Gomes M. B., Piccirillo L. J., Nogueira V. G., Matos H. J. Acute-phase proteins among patients with type 1 diabetes. Diabetes Metab: 2003; 29 405 411
20. Esposito K., Giugliano D., Nappo F., Marfella R. Campanian Postprandial Hyperglycemia Study G Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation: 2004; 110 214 219
21. Gonzalez-Clemente J. M., Mauricio D., Richart C., Broch M., Caixas A., Megia A., Gimenez-Palop O., Simon I., Martinez-Riquelme A., Gimenez-Perez G., Vendrell J. Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. Clin Endocrinol: 2005; 63 525 529
22. Ritter L. S., Orozco J. A., Coull B. M., McDonagh P. F., Rosenblum W. I. Leukocyte accumulation and hemodynamic changes in the cerebral microcirculation during early reperfusion after stroke. Stroke: 2000; 31 1153 1161
23. Joussen A. M., Poulaki V., Qin W., Kirchhof B., Mitsiades N., Wiegand S. J., Rudge J., Yancopoulos G. D., Adamis A. P. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol: 2002; 160 501 509
24. Bemeur C., Ste-Marie L., Desjardins P., Vachon L., Butterworth R. F., Hazell A. S., Montgomery J. Dehydroascorbic acid normalizes several markers of oxidative stress and inflammation in acute hyperglycemic focal cerebral ischemia in the rat. Neurochem Int: 2005; 46 399 407
25. Lin B., Ginsberg M. D., Busto R., Li L. Hyperglycemia triggers massive neutrophil deposition in brain following transient ischemia in rats. Neuroscience letters: 2000; 278 1 4
26. Ste-Marie L., Hazell A. S., Bemeur C., Butterworth R., Montgomery J. Immunohistochemical detection of inducible nitric oxide synthase, nitrotyrosine and manganese superoxide dismutase following hyperglycemic focal cerebral ischemia. Brain Res: 2001; 918 10 19
27. Xie H., Ray P. E., Short B. L. NF-kappaB activation plays a role in superoxide-mediated cerebral endothelial dysfunction after hypoxia/reoxygenation. Stroke: 2005; 36 1047 1052
28. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes: 2005; 54 1615 1625
29. Carr M. E. Diabetes mellitus: a hypercoagulable state. Journal of diabetes and its complications: 2001; 15 44 54
30. Vinik A. I., Erbas T., Park T. S., Nolan R., Pittenger G. L. Platelet dysfunction in type 2 diabetes. Diabetes Care: 2001; 24 1476 1485
31. Thornalley P. J. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol: 2002; 50 37 57
32. Singh R., Barden A., Mori T., Beilin L. Advanced glycation end-products: a review. Diabetologia: 2001; 44 129 146
33. Thornalley P. J., Langborg A., Minhas H. S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J: 1999; 344 Pt 1 109 116
34. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y. Adiponectin an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation: 2000; 102 1296 1301
35. Soriano F. G., Virag L., Szabo C. Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. Journal of molecular medicine: 2001; 79 437 448
36. Madonna R., De Caterina R. Cellular and molecular mechanisms of vascular injury in diabetes - part I: pathways of vascular disease in diabetes. Vascular pharmacology: 2011; 54 68 74
37. Schafer A., Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol: 2008; 6 52 60
38. Wink D. A., Mitchell J. B. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radical Biol Med: 1998; 25 434 456
39. Iadecola C., Xu X., Zhang F., El-Fakahany E. E., Ross M. E. Marked induction of calcium-independent nitric oxide synthase activity after focal cerebral ischemia. J Cereb Blood Flow Metab: 1995; 15 52 59
40. Fujimura M., Morita-Fujimura Y., Kawase M., Copin J. C., Calagui B., Epstein C. J., Chan P. H. Manganese superoxide dismutase mediates the early release of mitochondrial cytochrome C and subsequent DNA fragmentation after permanent focal cerebral ischemia in mice. J Neurosci: 1999; 19 3414 3422
41. Marfella R., Quagliaro L., Nappo F., Ceriello A., Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest: 2001; 108 635 636
42. Zhang Z., Apse K., Pang J., Stanton R. C. High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem: 2000; 275 40042 40047
43. Brzezinska A. K., Gebremedhin D., Chilian W. M., Kalyanaraman B., Elliott S. J. Peroxynitrite reversibly inhibits Ca(2+)-activated K(+) channels in rat cerebral artery smooth muscle cells. Am J Physiol Heart Circ Physiol: 2000; 278 H1883 H1890
44. Ceriello A., Falleti E., Motz E., Taboga C., Tonutti L., Ezsol Z., Gonano F., Bartoli E. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res: 1998; 30 146 149
45. Beckman J. A., Creager M. A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA: 2002; 287 2570 2581
46. Matsumoto K., Sera Y., Abe Y., Tominaga T., Yeki Y., Miyake S. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract: 2004; 64 225 228
47. Wilcox R., Bousser M. G., Betteridge D. J., Schernthaner G., Pirags V., Kupfer S., Dormandy J. Investigators PR Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke: 2007; 38 865 873
48. Simard J. M., Yurovsky V., Tsymbalyuk N., Melnichenko L., Ivanova S., Gerzanich V. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke: 2009; 40 604 609
49. Selvin E., Hirsch A. T. Contemporary risk factor control and walking dysfunction in individuals with peripheral arterial disease: NHANES 1999-2004. Atherosclerosis: 2008; 201 425 433
50. Venna V. R., Li J., Hammond M. D., Mancini N. S., McCullough L. D. Chronic metformin treatment improves post-stroke angiogenesis and recovery after experimental stroke. Eur J Neurosci: 2014; 39 2129 2138
51. Meinert C. L., Knatterud G. L., Prout T. E., Klimt C. R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes: 1970; 19 Suppl 789 830
52. Buse J. B., Rosenstock J., Sesti G., Schmidt W. E., Montanya E., Brett J. H., Zychma M., Blonde L. Group L-S Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet: 2009; 374 39 47
53. Balfour J. A., McTavish D. Acarbose: An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs: 1993; 46 1025 1054
54. Mooradian A. D., Thurman J. E. Drug therapy of postprandial hyperglycaemia. Drugs: 1999; 57 19 29
55. He K., Shi J. C., Mao X. M. Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients. Ther Clinl Risk Manag: 2014; 10 505 511
56. Weng J., Soegondo S., Schnell O., Sheu WH H., Grzeszczak W., Watada H., Yamamoto N., Kalra S. Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database. Diabetes/Metab Res Rev: 2015; 31 155 167
57. Scheen A. J. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs: 2003; 63 933 951
58. van de Laar F. A., Lucassen P. L., Akkermans R. P., van de Lisdonk E. H., Rutten G. E., van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care: 2005; 28 154 163
59. Derosa G., Maffioli P. Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents α-Glucosidase inhibitors and their use in clinical practice. Archiv Med Sci: 2012; 8 899
60. Kaku K. Efficacy of voglibose in type 2 diabetes. Expert Opin Pharmacother: 2014; 15 1181 1190
61. Moritoh Y., Takeuchi K., Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther: 2009; 329 669 676
62. Laube H. Acarbose: An Update of Its Therapeutic Use in Diabetes Treatment. Clin Drug Investig: 2002; 22 141 156
63. Philip E., Sundaram M. L., Das R., Chauhan S. K., Deshpande S., Ambhore S., Rathod R., Manjrekar P. Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study. Indian J Endocrinol Metab: 2013; 17 S674
64. Nathan D. M., Buse J. B., Davidson M. B., Ferrannini E., Holman R. R., Sherwin R., Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care: 2008; 31 173 175
65. Haffner S. M., Valdez R., Morales P. A., Mitchell B. D., Hazuda H. P., Stern M. P. Greater effect of glycemia on incidence of hypertension in women than in men. Diabetes Care: 1992; 15 1277 1284
66. Satoh N., Shimatsu A., Yamada K., Aizawa-Abe M., Suganami T., Kuzuya H., Ogawa Y. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism: 2006; 55 786 793
67. Lee S. M. The effect of chronic alpha-glycosidase inhibition on diabetic nephropathy in the db/db mouse. Diabetes: 1982; 31 249 254
68. Chen J. M., Chang C. W., Lin Y. C., Horng J. T., Sheu W. H. Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study. J Diabetes Res: 2014; 2014: 812628
69. Chiasson J. L., Josse R. G., Gomis R., Hanefeld M., Karasik A., Laakso M. Group S-NTR Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA: 2003; 290 486 494
70. Chiasson J. L., Josse R. G., Gomis R., Hanefeld M., Karasik A., Laakso M. Group S-NTR Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet: 2002; 359 2072 2077
71. Bavenholm P. N., Efendic S. Postprandial hyperglycaemia and vascular damage - the benefits of acarbose. Diabetes Vasc Disease Res: 2006; 3 72 79
72. Hanefeld M., Chiasson J. L., Koehler C., Henkel E., Schaper F., Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke: 2004; 35 1073 1078
73. Shimabukuro M., Higa N., Chinen I., Yamakawa K., Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab: 2006; 91 837 842
74. Wascher T. C., Schmoelzer I., Wiegratz A., Stuehlinger M., Mueller-Wieland D., Kotzka J., Enderle M. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Investig: 2005; 35 551 557
75. Azuma K., Toyofuku Y., Iesaki T., Otsuka A., Tanaka A., Mita T., Hirose T., Tanaka Y., Daida H., Kawamori R., Watada H. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem Biophys Res commun: 2006; 345 688 693
76. Vallejo S., Angulo J., Peiro C., Cercas E., Sanchez-Ferrer A., Nevado J., Llergo J. L., Rodriguez-Manas L., Sanchez-Ferrer C. F. Treatment with acarbose may improve endothelial dysfunction in streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol: 2000; 36 255 262
77. Rosen P., Osmers A. Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose. Horm Metab Res: 2006; 38 575 586
78. Aydin A., Orhan H., Sayal A., Ozata M., Sahin G., Isimer A. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clin Biochem: 2001; 34 65 70
79. Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Investig: 1994; 24 03 3 10
80. Becker L. B. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res: 2004; 61 461 470
81. Paulson D. J. The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res: 1997; 34 104 112
82. Frantz S., Calvillo L., Tillmanns J., Elbing I., Dienesch C., Bischoff H., Ertl G., Bauersachs J. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose. FASEB J: 2005; 19 591 593
83. Meneilly G. S., Ryan E. A., Radziuk J., Lau D. C., Yale J. F., Morais J., Chiasson J. L., Rabasa-Lhoret R., Maheux P., Tessier D., Wolever T., Josse R. G., Elahi D. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes care: 2000; 23 1162 1167
84. Laube H., Linn T., Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes: 1998; 106 231 233
85. Delgado H., Lehmann T., Bobbioni-Harsch E., Ybarra J., Golay A. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab: 2002; 28 195 200
86. Hanefeld M., Haffner S. M., Menschikowski M., Koehler C., Temelkova-Kurktschiev T., Wildbrett J., Fischer S. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Diabetes Res Clin Pract: 2002; 55 221 227
87. Rudofsky G. Jr, Reismann P., Schiekofer S., Petrov D., von Eynatten M., Humpert P. M., Isermann B., Muller-Hoff C., Thai T. P., Lichtenstein S., Bartsch U., Hamann A., Nawroth P., Bierhaus A. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs. Horm Metab Res: 2004; 36 630 638
88. Shinoda Y., Inoue I., Nakano T., Seo M., Sassa M., Goto S., Awata T., Komoda T., Katayama S. Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance. Metabolism: 2006; 55 935 939
89. Ceriello A., Taboga C., Tonutti L., Giacomello R., Stel L., Motz E., Pirisi M. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia: 1996; 39 469 473
90. Kado S., Murakami T., Aoki A., Nagase T., Katsura Y., Noritake M., Matsuoka T., Nagata N. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract: 1998; 41 49 55
91. Scott R., Lintott C. J., Zimmet P., Campbell L., Bowen K., Welborn T. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? Diabetes Res Clin Pract: 1999; 43 179 185
92. Kawamura T., Egusa G., Fujikawa R., Watanabe T., Oda K., Kataoka S., Takayama S., Kubo K., Yamamoto S., Noma K., Orita R., Yamakido M. Effect of acarbose on glycemic control and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Curr Ther Res 59 97 106
93. Mughal M. A., Memon M. Y., Zardari M. K., Tanwani R. K., Ali M. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes. J Pakistan Med Assoc: 2000; 50 152 156
94. Yamasaki Y., Katakami N., Hayaishi-Okano R., Matsuhisa M., Kajimoto Y., Kosugi K., Hatano M., Hori M. alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract: 2005; 67 204 210
95. Reaven G. M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med: 1996; 334 374 381
96. Rosenbaum P., Peres R. B., Zanella M. T., Ferreira S. R. Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters. Brazilian J Med Biol Res: 2002; 35 877 884
97. Rosenthal J., Mauersberger H. Effects on Blood Pressure of the α-Glucosidase Inhibitor Acarbose Compared with the Insulin Enhancer Glibenclamide in Patients with Hypertension and Type 2 Diabetes Mellitus. Clin Drug Investig: 2002; 22 695 701
98. Shibao C., Gamboa A., Diedrich A., Dossett C., Choi L., Farley G., Biaggioni I. Acarbose an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. Hypertension: 2007; 50 54 61
99. Van de Laar F. A., Lucassen P. L., Akkermans R. P., Van de Lisdonk E. H., Rutten G. E., Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. In: The Cochrane Collaboration (ed.). Cochrane Database of Systematic Reviews. Chichester, UK John Wiley & Sons, Ltd.: 2005